Autres langues Omeros Corporation

Actions

OMER

US6821431029

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/08/2026			Varia. 5j.	Varia. 1 janv.
13,62 ^USD	+2,79%		+8,44%	-20,70%

26/06	Omeros Corporation fait le point sur la demande d'autorisation de mise sur le marché européen du narsoplimab dans la MAT-GCSH	CI
26/06	Omeros sollicite un réexamen de l'EMA après un avis défavorable sur la demande de commercialisation du narsoplimab	MT

Autres langues

10/08	Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
03/08	CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
26/06	Omeros Corporation Provides Update On European Marketing Authorization Application For Narsoplimab In TA-TMA
26/06	Omeros to Seek EMA Review After Negative Opinion on Narsoplimab Marketing Application
26/06	Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
26/06	Top Premarket Decliners
15/06	Omeros Announces Webcast Details for Annual Meeting of Shareholders
13/05	Omeros Q1 Adjusted Loss Narrows
13/05	Omeros: Q1 Earnings Snapshot
13/05	Tranche Update on Omeros Corporation's Equity Buyback Plan announced on December 1, 2025.
13/05	Omeros Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
13/05	Earnings Flash (OMER) Omeros Corporation Reports Q1 Revenue $9.9M, vs. FactSet Est of $4.2M
13/05	Earnings Flash (OMER) Omeros Corporation Posts Q1 Adjusted Loss $0.24 per Share, vs. FactSet Est of $-0.39
13/05	Omeros Corporation Reports First Quarter 2026 Financial Results
11/05	Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
20/04	Sagimet Biosciences Inc Announces Executive Changes, Effective April 20, 2026
20/04	Sagimet Biosciences Inc. Announces Executive Changes, Effective April 20, 2026
17/04	Omeros Corporation - CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA
16/04	CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
31/03	Omeros Swings to Profit in Q4
31/03	Omeros: Q4 Earnings Snapshot
31/03	Tranche Update on Omeros Corporation's Equity Buyback Plan announced on December 1, 2025.
31/03	Omeros Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2025
31/03	Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
26/03	Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026